Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in developing ACE2 derivatives against SARS-CoV-2
Haoran Zhang, Panjing Lv, Jingrui Jiang, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 5, pp. e369-e378
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Lipid Metabolism Modulation during SARS-CoV-2 Infection: A Spotlight on Extracellular Vesicles and Therapeutic Prospects
Heloísa D’Ávila, Claudia Natércia Rocha Lima, Pollianne Garbero Rampinelli, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 640-640
Open Access | Times Cited: 20
Progress in antileishmanial drugs: Mechanisms, challenges, and prospects
Haoran Zhang, Ruixi Yan, Yahui Liu, et al.
PLoS neglected tropical diseases (2025) Vol. 19, Iss. 1, pp. e0012735-e0012735
Open Access | Times Cited: 2
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
Structural and functional properties of the SARS-CoV-2 spike protein: Potential vaccine and drug development for COVID-19
Reed L. Berkowitz, David A. Ostrov
Elsevier eBooks (2025), pp. 57-74
Closed Access
Development of Stable, Maleimide-Functionalized Peptidoliposomes Against SARS-CoV-2
Olga Michel, Aleksandra Kaczorowska, Lucyna Matusewicz, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1629-1629
Open Access
Antiandrogens as Therapies for COVID-19: A Systematic Review
Massimiliano Cani, Samantha Epistolio, Giulia Dazio, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 298-298
Open Access | Times Cited: 4
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Rohan Ameratunga, A. M. Jordan, Klaus Lehnert, et al.
Antiviral Research (2024) Vol. 227, pp. 105894-105894
Closed Access | Times Cited: 2
Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics
Vinayakumar Siragam, Mariam Maltseva, Nicolas Castonguay, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 7
Open Access | Times Cited: 2
Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study
Rui Song, Xiaoyou Chen, Baoliang Li, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 7
Global trends in research on endothelial cells and sepsis between 2002 and 2022: A systematic bibliometric analysis
Yue Shi, Shunpan Ji, Yuhai Xu, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23599-e23599
Open Access | Times Cited: 7
In planta deglycosylation improves the SARS-CoV-2 neutralization activity of recombinant ACE2-Fc
Shiva Izadi, Ulrike Vavra, Stanislav Melnik, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 6
A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide
Stefania Glieca, Davide Cavazzini, Elisabetta Levati, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 191, pp. 106609-106609
Open Access | Times Cited: 5
Regulation of Peptidase Activity beyond the Active Site in Human Health and Disease
Ana Obaha, Marko Novinec
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 17120-17120
Open Access | Times Cited: 5
Mutation Trajectory of Omicron SARS-CoV-2 Virus, Measured by Principal Component Analysis
Tomokazu Konishi, Toa Takahashi
COVID (2024) Vol. 4, Iss. 4, pp. 571-581
Open Access | Times Cited: 1
A Piecewise Design Approach to Engineering a Miniature ACE2 Mimic to Bind SARS-CoV-2
Yashavantha L. Vishweshwaraiah, Brianna Hnath, Jian Wang, et al.
ACS Applied Bio Materials (2024) Vol. 7, Iss. 5, pp. 3238-3246
Closed Access | Times Cited: 1
Host Cell Proteases Involved in Human Respiratory Viral Infections and Their Inhibitors: A Review
Bailey Lubinski, Gary R. Whittaker
Viruses (2024) Vol. 16, Iss. 6, pp. 984-984
Open Access | Times Cited: 1
Advances in Angiotensin Converting Enzyme-2 and Renin Angiotensin System Against COVID 19: A Pharmacotherapy and Physicochemical Review
Suhad Hafidh
Research Review (2023)
Open Access | Times Cited: 4
ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks
Mohamed A. Alfaleh, Reem M. Alsulaiman, Sarah A. Almahboub, et al.
Antibody Therapeutics (2023) Vol. 7, Iss. 1, pp. 53-66
Open Access | Times Cited: 4
Host Cell Proteases Involved in Human Respiratory Viral Infections and Their Inhibitors: A Review
Bailey Lubinski, Gary R. Whittaker
(2024)
Open Access | Times Cited: 1
In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants
Jenny Andrea Arévalo-Romero, Gina López-Cantillo, Sara Moreno-Jiménez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10802-10802
Open Access | Times Cited: 1
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery
Sopisa Benjakul, Aina Anthi, Anette Kolderup, et al.
PNAS Nexus (2023) Vol. 2, Iss. 12
Open Access | Times Cited: 3
Conversion of Host Cell Receptor into Virus Destructor by Immunodisc to Neutralize Diverse SARS‐CoV‐2 Variants
Jaehyeon Hwang, Beom Kyu Kim, Seokoh Moon, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 14
Closed Access
Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment
Mandeep Kaur, Rahul Sandhu, Akriti Aggarwal
Infectious Disorders - Drug Targets (2024) Vol. 25, Iss. 1
Open Access
A Nanobody Interaction with SARS-CoV-2 Spike Allows the Versatile Targeting of Lentivirus Vectors
Ayna Alfadhli, Timothy A. Bates, Robin Lid Barklis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Peptide S4 is an entry inhibitor of SARS-CoV-2 infection
Zhiyu Liang, Jiamei Wang, Huan Zhang, et al.
Virology (2024) Vol. 597, pp. 110149-110149
Closed Access
Page 1 - Next Page

Scroll to top